219 related articles for article (PubMed ID: 20511978)
1. Adalimumab-induced acute pneumonitis in a patient with rheumatoid arthritis.
Dascalu C; Mrejen-Shakin K; Bandagi S
J Clin Rheumatol; 2010 Jun; 16(4):172-4. PubMed ID: 20511978
[TBL] [Abstract][Full Text] [Related]
2. A comparison of safety profiles of tumour necrosis factor α inhibitors and rituximab therapy in patients with rheumatoid arthritis and chronic hepatitis C.
Chen YM; Chen HH; Chen YH; Hsieh TY; Hsieh CW; Hung WT; Lan JL; Chen DY
Ann Rheum Dis; 2015 Mar; 74(3):626-7. PubMed ID: 25452310
[No Abstract] [Full Text] [Related]
3. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
4. Pseudolymphomatoid cutaneous leishmaniasis in a patient treated with adalimumab for rheumatoid arthritis.
Baltà-Cruz S; Alsina-Glbert M; Mozos-Rocafort A; Cervera C; Colomo-Saperas L; Del Río A; Estrach-Panella T
Acta Derm Venereol; 2009; 89(4):432-3. PubMed ID: 19688168
[No Abstract] [Full Text] [Related]
5. Alopecia areata universalis during treatment of rheumatoid arthritis with anti-TNF-alpha antibody (adalimumab).
Chaves Y; Duarte G; Ben-Said B; Tebib J; Berard F; Nicolas JF
Dermatology; 2008; 217(4):380. PubMed ID: 18849606
[No Abstract] [Full Text] [Related]
6. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
7. Dermatomyositis in patients with rheumatoid arthritis during adalimumab therapy.
Nagashima T; Minota S
J Rheumatol; 2011 Mar; 38(3):574; author reply 575. PubMed ID: 21362792
[No Abstract] [Full Text] [Related]
8. [The pulmonological manifestations of rheumatoid arthritis].
Bernscherer G; Karabélyos C; Tarján Z
Orv Hetil; 2008 Jul; 149(29):1355-61. PubMed ID: 18617467
[TBL] [Abstract][Full Text] [Related]
9. Pyoderma gangrenosum in a patient with seronegative rheumatoid arthritis during therapy with adalimumab: toxic effects of adalimumab or failure of adalimumab to prevent the onset of this phenomenon?
Stichenwirth M; Riedl E; Pehamberger H; Tappeiner G
Arch Dermatol; 2008 Jun; 144(6):817-8. PubMed ID: 18559788
[No Abstract] [Full Text] [Related]
10. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
Breedveld FC; Weisman MH; Kavanaugh AF; Cohen SB; Pavelka K; van Vollenhoven R; Sharp J; Perez JL; Spencer-Green GT
Arthritis Rheum; 2006 Jan; 54(1):26-37. PubMed ID: 16385520
[TBL] [Abstract][Full Text] [Related]
11. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases.
Perez-Alvarez R; Perez-de-Lis M; Diaz-Lagares C; Pego-Reigosa JM; Retamozo S; Bove A; Brito-Zeron P; Bosch X; Ramos-Casals M
Semin Arthritis Rheum; 2011 Oct; 41(2):256-64. PubMed ID: 21277618
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis.
Ostör AJ; Chilvers ER; Somerville MF; Lim AY; Lane SE; Crisp AJ; Scott DG
J Rheumatol; 2006 Mar; 33(3):622-8. PubMed ID: 16511933
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.
Burmester GR; Mariette X; Montecucco C; Monteagudo-Sáez I; Malaise M; Tzioufas AG; Bijlsma JW; Unnebrink K; Kary S; Kupper H
Ann Rheum Dis; 2007 Jun; 66(6):732-9. PubMed ID: 17329305
[TBL] [Abstract][Full Text] [Related]
14. Interstitial pneumonitis and anti-tumor necrosis factor-alpha therapy.
Roos JC; Chilvers ER; Ostor AJ
J Rheumatol; 2007 Jan; 34(1):238-9; author reply 239. PubMed ID: 17216703
[No Abstract] [Full Text] [Related]
15. Adalimumab-induced asthma.
Bennett AN; Wong M; Zain A; Panayi G; Kirkham B
Rheumatology (Oxford); 2005 Sep; 44(9):1199-200. PubMed ID: 15870147
[No Abstract] [Full Text] [Related]
16. Safety of biologic therapies--an update.
Keystone EC
J Rheumatol Suppl; 2005 Mar; 74():8-12. PubMed ID: 15742458
[TBL] [Abstract][Full Text] [Related]
17. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.
van Rijthoven AW; Bijlsma JW; Canninga-van Dijk M; Derksen RH; van Roon JA
Rheumatology (Oxford); 2006 Oct; 45(10):1317-9. PubMed ID: 16844698
[No Abstract] [Full Text] [Related]
18. Severe polymyositis and flare in autoimmunity following treatment with adalimumab in a patient with overlapping features of polyarthritis and scleroderma.
Liozon E; Ouattara B; Loustaud-Ratti V; Vidal E
Scand J Rheumatol; 2007; 36(6):484-6. PubMed ID: 18092275
[No Abstract] [Full Text] [Related]
19. Mycobacterium chelonae infection associated with adalimumab therapy.
Díaz F; Urkijo JC; Mendoza F; de la Viuda JM; Blanco M; Unzurrunzaga A; Ayarza R
Scand J Rheumatol; 2008; 37(2):159-60. PubMed ID: 18415777
[No Abstract] [Full Text] [Related]
20. Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody.
Baker DE
Rev Gastroenterol Disord; 2004; 4(4):196-210. PubMed ID: 15580154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
